Human-Based Atrial Fibrillation Model
The Challenge
Atrial-selective cardiac testing remains underrepresented in preclinical workflows, despite the growing clinical relevance of atrial fibrillation (AF) as the most common cardiac arrhythmia worldwide. Most in vitro cardiac assays are ventricular-based and fail to replicate atrial electrophysiological properties or tachyarrhythmic stress. As a result, compounds targeting atrial mechanisms or carrying pro-arrhythmic potential may be mischaracterized or missed altogether.
Our Solution
We provide a human-based AF-like model using hiPSC-derived atrial cardiomyocytes subjected to chronic electrical tachypacing at 2.5 Hz. This setup induces electrophysiological remodeling and creates a phenotype reflective of AF-like vulnerability. Clients can evaluate atrial-specific drug effects, arrhythmia susceptibility, and beat pattern changes under defined pacing stress. The model is ideal for atrial drug screening, mechanism-of-action studies, and atrial-selective safety evaluation in a controlled and reproducible format.
